Immune to Cancer: The CRI Blog
-
Highlights of the 2nd Annual Rational Combinations 360° Conference
Biomarkers will be crucial to taking advantage of combination immunotherapy’s full potential
-
Nivolumab Approved for Patients with Chemotherapy-Resistant, Metastatic, MSI-H Colorectal Cancer
Nivolumab becomes second checkpoint immunotherapy approved for colorectal cancer
-
Immunotherapy Makes History with Latest Cancer Approval
The FDA’s biomarker-based approval of Keytruda was the first of its kind
-
FDA approves Keytruda combo for first-line lung cancer treatment
Patients in the U.S. who have advanced nonsquamous non-small cell lung cancer can now receive Keytruda as…
-
Durvalumab Becomes Newest Immunotherapy Approved for Advanced Bladder Cancer
Durvalumab marks AstraZeneca’s first immunotherapy approval
-
AACR17 Update: Checkpoint Immunotherapy Clinical Trials in Melanoma and Lung Cancer
In-depth analysis of long-term clinical trial data provides important insights for doctors treating…
-
AACR17 Update: CAR T Cells, Regulatory T Cells, and the Future of Immunotherapy
Day two addressed several strategies to improve immunotherapy’s precision and effectiveness
-
AACR17 Update: Taking Immunotherapy to the Next Level
After cancer immunotherapy’s initial successes, new challenges are being confronted
-
Pembrolizumab Approved for Children and Adults with Hard-to-Treat Hodgkin Lymphoma
Pembrolizumab is second anti-PD-1 drug approved for adults with cHL, first for any childhood cancer